By Max Kozlov A build-up of sticky goo that traps neurons in an appetite-control centre in the brain has been implicated in worsening diabetes and obesity, according to research on mice1. The goo also prevents insulin from reaching brain neurons that control hunger. Inhibiting production of the goo led mice to lose weight, experiments found. These findings points to a new driver of metabolic disorders and could help scientists to identify targets for drugs to treat these conditions. These results were published today in Nature. Metabolic diseases such as type 2 diabetes and obesity can develop when the body’s cells become insensitive to insulin, a hormone that regulates blood-sugar levels. Scientists searching for the mechanism that causes this insulin resistance have homed in on a part of the brain called the arcuate nucleus of the hypothalamus, which senses insulin levels and, in response, adjusts energy expenditure and sensations of hunger. As the animals develop insulin resistance, a type of cellular scaffolding, called the extracellular matrix, that holds the hunger neurons in place becomes a disorganized goo. Previously, researchers had noticed that this scaffolding changes when mice are fed a high-fat diet2. The researchers wanted to see whether these brain changes might drive insulin resistance rather than merely developing alongside it. The authors fed mice a high-fat, high-sugar diet for 12 weeks and monitored the scaffolding around the hunger neurons by taking tissue samples and monitoring gene activity. © 2024 Springer Nature Limited

Keyword: Obesity
Link ID: 29489 - Posted: 09.21.2024

By Gina Kolata and Stephanie Nolen The Lasker Awards, a prestigious set of prizes given for advances in medicine and public health research, were given on Thursday to scientists whose research helped lead to the discovery of a new class of obesity drugs, infectious disease specialists who worked on the drivers of H.I.V. infection and how to stop it, and a scientist who discovered a way the body protects itself from infectious diseases and cancer. The Laskers are highly regarded in the fields of biomedicine and are sometimes seen as foretelling recipients of the Nobel Prizes in the sciences. This year’s Lasker-DeBakey Clinical Medical Research Award went to three scientists for their work on GLP-1, the hormone that led to drugs like Wegovy (the same compound is the basis for Ozempic), which have transformed the treatment of obesity. They are Dr. Joel Habener, Svetlana Mojsov and Lotte Bjerre Knudsen. Each of the three honorees played a role at a key moment: finding the new hormone; finding the biologically active shorter form of GLP-1; and, finally, showing that the shorter form elicits weight loss. Of course, as almost always happens in science, many others also played key roles, and the Lasker Foundation mentioned some as part of its citation. And one of the honorees, Dr. Mojsov, is receiving what many deem a long overdue recognition. The story of GLP-1 begins with Dr. Habener, an endocrinologist who arrived in the mid-1970s at Massachusetts General Hospital, where he decided to work on diabetes. Most of the focus had been on insulin, which lowers blood sugar levels. But there is another hormone, glucagon, that raises it. Dr. Habener decided to try to find the gene for glucagon, hoping it would lead to a way to squelch the hormone and so lower blood sugar. Working with anglerfish, he discovered a gene for another mysterious protein that resembles glucagon. © 2024 The New York Times Company

Keyword: Obesity; Neuroimmunology
Link ID: 29488 - Posted: 09.21.2024

By Daniela J. Lamas In the near future, the story of drugs like Ozempic may no longer be primarily about weight loss and diabetes. We now know that these drugs can reduce heart and kidney disease. They could very well slow the progression of dementia. They might help women struggling with infertility to get pregnant. They are even tied to lower mortality from Covid. It’s easy to attribute this to the dramatic weight loss provided by Ozempic and other drugs in its class, known as GLP-1 receptor agonists. But that isn’t the whole story. Rather, the drugs’ numerous benefits are pointing to an emerging cause of so much human disease: inflammation. As a critical care doctor, I have long considered inflammation a necessary evil, the mechanism through which our bodies sound an alarm and protect us from threat. But a growing body of research complicates that understanding. Inflammation is not just a marker of underlying disease but also a driver of it. The more medicine learns about inflammation, the more we are learning about heart disease and memory loss. This should serve as a reminder of the delicate balance that exists in our bodies, of the fact that the same system that protects us can also cause harm. Inflammation is the body’s response to infection or injury. Our innate immune system — the body’s first line of defense against bacterial or viral intruders — protects us by triggering an inflammatory response, a surge of proteins and hormones that fight infection and promote healing. Without that response, we would die of infectious disease in childhood. But by the time we make it to our 50s and beyond, our innate immune system can become more of a hindrance as inflammation begins to take a toll on the body. Acute inflammation, which happens in response to an illness, for instance, is often something we can see — an infected joint is swollen and red. But chronic inflammation is usually silent. Like high blood pressure, it’s an invisible foe. Sign up for the Opinion Today newsletter Get expert analysis of the news and a guide to the big ideas shaping the world every weekday morning. Get it sent to your inbox. © 2024 The New York Times Company

Keyword: Obesity
Link ID: 29487 - Posted: 09.21.2024

Brian Mann For the first time in decades, public health data shows a sudden and hopeful drop in drug overdose deaths across the U.S. "This is exciting," said Dr. Nora Volkow, head of the National Institute On Drug Abuse [NIDA], the federal laboratory charged with studying addiction. "This looks real. This looks very, very real." National surveys compiled by the Centers for Disease Control and Prevention already show an unprecedented decline in drug deaths of roughly 10.6 percent. That's a huge reversal from recent years when fatal overdoses regularly increased by double-digit percentages. Some researchers believe the data will show an even larger decline in drug deaths when federal surveys are updated to reflect improvements being seen at the state level, especially in the eastern U.S. "In the states that have the most rapid data collection systems, we’re seeing declines of twenty percent, thirty percent," said Dr. Nabarun Dasgupta, an expert on street drugs at the University of North Carolina. According to Dasgupta's analysis, which has sparked discussion among addiction and drug policy experts, the drop in state-level mortality numbers corresponds with similar steep declines in emergency room visits linked to overdoses. Dr. Nabarun Dasgupta, a researcher at the University of North Carolina, is an expert on the U.S. street drug supply. He believes data shows a sudden drop in drug overdose deaths nationwide that could already by saving Dr. Nabarun Dasgupta, a researcher at the University of North Carolina, is an expert on the U.S. street drug supply. He believes data shows a sudden drop in drug overdose deaths nationwide that could already by saving "roughly 20,000 lives" per year. © 2024 npr

Keyword: Drug Abuse
Link ID: 29486 - Posted: 09.21.2024

By Laura Sanders Pregnancy overhauls a woman’s body. The brain is no exception. A detailed study of a woman’s brain before, during and after pregnancy revealed sweeping neural changes, some of which stuck around months after her baby was born. The dataset, published September 16 in Nature Neuroscience, is the first comprehensive view of the neural changes that accompany gestation — a sort of “what to expect when you’re expecting” for the brain. “The results of this case study are astonishing,” says neuroscientist Clare McCormack of New York University Langone Health. “Here we see, for the first time in humans, the extent of brain changes that are under way throughout pregnancy.” This research joins a small number of other studies aimed at understanding the female brain at various stages of life (SN: 9/29/22). Collectively, the work suggests that the process of becoming a mother, called matrescence, is another stage of development, like the brain overhaul that happens in adolescence (SN: 2/27/23). Earlier experiments mostly compared brains of women before and after their pregnancies and inferred what happens in between (SN: 12/19/16). “There was a missing piece,” McCormack says. “The nine months of pregnancy was a black box, and we could only guess what that trajectory looks like.” With four MRI scans before pregnancy, 15 scans during pregnancy and seven scans in the two years after the baby was born, the new study follows the entire arc for one mother. © Society for Science & the Public 2000–2024.

Keyword: Sexual Behavior; Hormones & Behavior
Link ID: 29485 - Posted: 09.18.2024

Jon Hamilton Scientists have created a virtual brain network that can predict the behavior of individual neurons in a living brain. The model is based on a fruit fly’s visual system, and it offers scientists a way to quickly test ideas on a computer before investing weeks or months in experiments involving actual flies or other lab animals. “Now we can start with a guess for how the fly brain might work before anyone has to make an experimental measurement,” says Srini Turaga, a group leader at the Janelia Research Campus, a part of the Howard Hughes Medical Institute (HHMI). The approach, described in the journal Nature, also suggests that power-hungry artificial intelligence systems like ChatGPT might consume much less energy if they used some of the computational strategies found in a living brain. A fruit fly brain is “small and energy efficient,” says Jakob Macke, a professor at the University of Tübingen and an author of the study. “It’s able to do so many computations. It’s able to fly, it’s able to walk, it’s able to detect predators, it’s able to mate, it’s able to survive—using just 100,000 neurons.” In contrast, AI systems typically require computers with tens of billions of transistors. Worldwide, these systems consume as much power as a small country. “When we think about AI right now, the leading charge is to make these systems more power efficient,” says Ben Crowley, a computational neuroscientist at Cold Spring Harbor Laboratory who was not involved in the study. Borrowing strategies from the fruit fly brain might be one way to make that happen, he says. © 2024 npr

Keyword: Brain imaging; Evolution
Link ID: 29484 - Posted: 09.18.2024

By Roni Caryn Rabin Adults under age 50 have been developing breast cancer and colorectal cancer at increasingly higher rates over the last six decades, and alcohol use may be one factor driving the trend, according to a scientific report published on Wednesday. The report, by the American Association for Cancer Research, highlights scientific breakthroughs that have led to new anticancer drugs and improved overall survival. But the authors also described a troubling pattern: Even as cancer death rates have declined, the overall incidence of several cancers has been rising inexplicably, with an especially alarming increase among younger adults in cancers of the gastrointestinal system, like colorectal cancer. The report estimates that 40 percent of all cancer cases are associated with modifiable risk factors. It recommends reducing alcohol consumption, along with making lifestyle changes such as avoiding tobacco, maintaining a healthy diet and weight, exercising, avoiding ultraviolet radiation and minimizing exposure to pollutants. The authors called for raising awareness through public messaging campaigns and adding cancer-specific warning labels to alcoholic beverages. The recommendations come amid a radical rethinking of the putative health benefits of moderate alcohol consumption, which for years was considered to be protective against heart disease. Just last month, a large study that followed more than 135,000 older British adults for over a decade found that moderate and light drinkers did not benefit from a reduction in heart disease when compared with occasional drinkers. And both moderate and light drinkers experienced more cancer deaths than occasional drinkers, a finding accentuated among low-income seniors and those with existing health problems. © 2024 The New York Times Company

Keyword: Drug Abuse
Link ID: 29483 - Posted: 09.18.2024

By Julian Nowogrodzki Millions of adults around the world take potent drugs such as Wegovy to shed pounds. Should kids do the same? That question is growing more urgent in the face of mounting evidence that children and adolescents, as well as adults, slim down if they take the latest generation of obesity drugs. Clinical trials1,2 have shown that many adolescents with obesity lose substantial amounts of weight on these drugs, which work by mimicking a natural hormone called glucagon-like peptide 1 (GLP-1). The GLP-1 mimics semaglutide, commonly sold as Ozempic and Wegovy, and liraglutide, marketed as Saxenda and Victoza, are approved in the United States and Europe to treat obesity in children as young as 12. Now a trial has produced some of the first data on anti-obesity drugs in even younger children: those aged 6 to 11. The study3 reports that children who were treated with liraglutide showed a decrease in their body mass index (BMI), a measure of obesity. The results were published on 10 September in The New England Journal of Medicine. Nature asked specialists in obesity about the costs and benefits of giving the GLP-1 mimics to youngsters who are still growing and developing. Why test powerful weight-loss drugs on kids? Most kids with obesity become teens with obesity and then adults with obesity. Many young children with severe obesity have “already developed significant health issues”, says physician Sarah Ro, who directs the University of North Carolina Physicians Network Weight Management Program and has served as a consultant to Novo Nordisk, the manufacturer of semaglutide. Her clinic in Hillsborough treats children with severe obesity who have health issues such as high blood pressure, type 2 diabetes or an advanced form of liver disease linked to excess weight. © 2024 Springer Nature Limited

Keyword: Obesity; Development of the Brain
Link ID: 29482 - Posted: 09.18.2024

By Max Kozlov A low-cost diabetes drug slows ageing in male monkeys and is particularly effective at delaying the effects of ageing on the brain, finds a small study that tracked the animals for more than three years1. The results raise the possibility that the widely used medication, metformin, could one day be used to postpone ageing in humans. Monkeys that received metformin daily showed slower age-associated brain decline than did those not given the drug. Furthermore, their neuronal activity resembled that of monkeys about six years younger (equivalent to around 18 human years) and the animals had enhanced cognition and preserved liver function. This study, published in Cell on 12 September, helps to suggest that, although dying is inevitable, “ageing, the way we know it, is not”, says Nir Barzilai, a geroscientist at the Albert Einstein College of Medicine in New York City, who was not involved in the study. Metformin has been used for more than 60 years to lower blood-sugar levels in people with type 2 diabetes — and is the second most-prescribed medication in the United States. The drug has long been known to have effects beyond treating diabetes, leading researchers to study it against conditions such as cancer, cardiovascular disease and ageing. Data from worms, rodents, flies and people who have taken the drug for diabetes suggest the drug might have anti-ageing effects. But its effectiveness against ageing had not been tested directly in primates, and it is unclear whether its potential anti-ageing effects are achieved by lowering blood sugar or through a separate mechanism. This led Guanghui Liu, a biologist who studies ageing at the Chinese Academy of Sciences in Beijing, and his colleagues to test the drug on 12 elderly male cynomolgus macaques (Macaca fasciucularis); another 16 elderly monkeys and 18 young or middle-aged animals served as a control group. Every day, treated monkeys received the standard dose of metformin that is used to control diabetes in humans. The animals took the drug for 40 months, which is equivalent to about 13 years for humans. © 2024 Springer Nature Limited

Keyword: Development of the Brain; Obesity
Link ID: 29481 - Posted: 09.14.2024

By Emily Anthes The common marmoset is a certified chatterbox. The small, South American monkey uses an array of chirps, whistles and trills to defend its territory, flag the discovery of food, warn of impending danger and find family members hidden by dense forest foliage. Marmosets also use distinct calls to address different individuals, in much the same way that people use names, new research suggests. The findings make them the first nonhuman primates known to use name-like vocal labels for individuals. Until this year, only humans, dolphins and parrots were known to use names when communicating. In June, however, scientists reported that African elephants appeared to use names, too; researchers made the discovery by using artificial intelligence-powered software to detect subtle patterns in the elephants’ low-pitched rumbles. In the new study, which was published in Science last month, a different team of researchers also used A.I. to uncover name-like labels hiding in the calls of common marmosets. The discovery, which is part of a burgeoning scientific effort to use sophisticated computational tools to decode animal communication, could help shed light on the origins of language. And it raises the possibility that name-bestowing behavior may be more widespread in the animal kingdom than scientists once assumed. “I think what it’s telling us is that it’s likely that animals actually have names for each other a lot more than maybe we ever conceived,” said George Wittemyer, a conservation biologist at Colorado State University who led the recent elephant study but was not involved in the marmoset research. “We just never were really looking properly.” Marmosets are highly social, forming long-term bonds with their mates and raising their offspring cooperatively in small family groups. They produce high-pitched, whistle-like “phee calls” to communicate with other marmosets who might be hidden among the treetops. “They start to exchange phee calls when they lose eyesight of each other,” said David Omer, a neuroscientist at the Hebrew University of Jerusalem who led the new study. © 2024 The New York Times Company

Keyword: Animal Communication; Language
Link ID: 29480 - Posted: 09.14.2024

By Angie Voyles Askham Nathaniel Daw has never touched a mouse. As professor of computational and theoretical neuroscience at Princeton University, he mainly works with other people’s data to construct models of the brain’s decision-making process. So when a collaborator came to him a few years ago with confusing data from mice that had performed a complex decision-making task in the lab, Daw says his best advice was just to fit the findings to the tried-and-true model of reward prediction error (RPE). That model relies on the idea that dopaminergic activity in the midbrain reflects discrepancies between expected and received rewards. Daw’s collaborator, Ben Engelhard, had measured the activity of dopamine neurons in the ventral tegmental area (VTA) of mice as they were deciding how to navigate a virtual environment. And although the virtual environment was more complex than what a mouse usually experiences in the real world, an RPE-based model should have held, Daw assumed. “It was obvious to me that there was this very simple story that was going to explain his data,” Daw says. But it didn’t. The neurons exhibited a wide range of responses, with some activated by visual cues and others by movement or cognitive tasks. The classic RPE model, it turned out, could not explain such heterogeneity. Daw, Engelhard and their colleagues published the findings in 2019. That was a wake-up call, Daw says, particularly after he watched videos of what the mice actually experienced in the maze. “It’s just so much more complicated, and high dimensional, and richer” than expected, he says. The idea that this richness could be reduced to such a simple model seems ludicrous now, he adds. “I was just so blinded.” © 2024 Simons Foundation

Keyword: Attention; Drug Abuse
Link ID: 29479 - Posted: 09.14.2024

By Christina Caron Julianna McLeod, 26, had her first psychotic episode while taking Vyvanse for attention deficit hyperactivity disorder last year. Ms. McLeod, who lives in Ontario, Canada, had taken the drug before but paused while pregnant with her first child and didn’t start taking it again until six months postpartum. Although the dose was 40 milligrams, she often forgot when she had last taken a pill. So she took one whenever she remembered — and may have ended up taking more than her prescribed daily dose. The delusions that she experienced made her feel euphoric and highly energetic. “I felt like my brain was exploding with connections,” she said. In her mind, she was a “super detective” who was uncovering the people and organizations that were secretly engaging in child sex trafficking. She even began to believe that someone was drugging her and her baby. Psychosis and mania are each known side effects of stimulant medications, and the Food and Drug Administration has added warnings to the medications’ labels saying that they may cause symptoms like hallucinations, delusional thinking or mania. But these side effects are considered rare — experienced by an estimated 1 in 1,000 patients — and have not been extensively researched. It can take months for someone to fully recover. A new study published on Thursday in The American Journal of Psychiatry suggests that dosage may play a role. It found that among people who took high doses of prescription amphetamines such as Vyvanse and Adderall, there was a fivefold increased risk of developing psychosis or mania for the first time compared with those who weren’t taking stimulants. The researchers defined a high dose as more than 40 milligrams of Adderall, 100 milligrams of Vyvanse or 30 milligrams of dextroamphetamine. The medium dosage (20 to 40 milligrams of Adderall, 50 to 100 milligrams of Vyvanse or 16 to 30 milligrams of dextroamphetamine) was associated with a 3.5 times higher risk of psychosis or mania. There was no increased risk of psychosis or mania among those who used methylphenidate drugs, like Concerta or Ritalin, regardless of the dose. © 2024 The New York Times Company

Keyword: ADHD; Schizophrenia
Link ID: 29478 - Posted: 09.14.2024

By Ellen Barry A study of adolescent brain development that tested children before and after coronavirus pandemic lockdowns in the United States found that girls’ brains aged far faster than expected, something the researchers attributed to social isolation. The study from the University of Washington, published on Monday in the Proceedings of the National Academy of Sciences, measured cortical thinning, a process that starts in either late childhood or early adolescence, as the brain begins to prune redundant synapses and shrink its outer layer. Thinning of the cortex is not necessarily bad; some scientists frame the process as the brain rewiring itself as it matures, increasing its efficiency. But the process is known to accelerate in stressful conditions, and accelerated thinning is correlated with depression and anxiety. Scans taken in 2021, after shutdowns started to lift, showed that both boys and girls had experienced rapid cortical thinning during that period. But the effect was far more notable in girls, whose thinning had accelerated, on average, by 4.2 years ahead of what was expected; the thinning in boys’ brains had accelerated 1.4 years ahead of what was expected. “That is a stunning difference,” said Patricia K. Kuhl, a director of the Institute for Learning and Brain Sciences at the University of Washington and one of the study’s authors. The results, she added, suggested that “a girl who came in at 11, and then returned to the lab at age 14, now has a brain that looks like an 18-year-old’s.” Dr. Kuhl attributed the change to “social deprivation caused by the pandemic,” which she suggested had hit adolescent girls harder because they are more dependent on social interaction — in particular, talking through problems with friends — as a way to release stress. The difference between the genders “is just as clear as night and day,” Dr. Kuhl said. “In the girls, the effects were all over the brain — all the lobes, both hemispheres.” © 2024 The New York Times Company

Keyword: Stress; Development of the Brain
Link ID: 29477 - Posted: 09.11.2024

Alzheimer’s disease impairs a patient by destroying neurons, which otherwise live for decades, and by disrupting communication among the remaining brain cells. As neurons die, the areas of the brain they constitute begin to atrophy. A detailed picture of the progression is still under investigation, and the disease follows different tracks in different patients, but researchers have found brains afflicted with Alzheimer’s typically atrophy along the same basic pattern. A better understanding of that pattern may provide the foundation for methods to diagnose the disease earlier, which in turn would give medication and lifestyle changes the best chance of slowing dementia. In broad strokes, here’s how Alzheimer’s tends to change a brain. © 2024 SCIENTIFIC AMERICAN,

Keyword: Alzheimers
Link ID: 29476 - Posted: 09.11.2024

By Frieda Klotz For five years, Clare Dolman took lithium to manage her bipolar disorder. The medicine kept her happy and well with few side effects, and she described it as a wonder drug. But when she began to plan for a pregnancy, her psychiatrist advised her to go off the medication to protect the fetus. This was 1988, and it was the standard guidance at the time. While Dolman experienced some stresses during the pregnancy, her mood remained stable. But soon after giving birth, she began to experience mild hallucinations. “I thought, yes, there’s something wrong here,” she recalled. “But I had the insight still to see that I was getting ill, and my husband knew I was getting ill because he had seen me really bad.” She went on to spend five weeks in the hospital. Clare Dolman at the launch of the Bipolar Commission at the U.K. Parliament. Dolman, who has bipolar disorder, stopped taking lithium during her own pregnancies more than 30 years ago. She later became a mental health advocate and has studied the experiences of pregnant women with the illness. Visual: Courtesy of Clare Dolman Bipolar disorder involves extreme fluctuations in mood and is classified into different types according to symptoms and severity. For women with the condition, pregnancy can be a fraught endeavor as they balance the health of their growing fetus with their own mental state. Many, like Dolman, stop taking the medications that keep them well — which can lead to a recurrence of symptoms — and some avoid pregnancy altogether.

Keyword: Schizophrenia; Sexual Behavior
Link ID: 29475 - Posted: 09.11.2024

Anna Bawden Health and social affairs correspondent An epilepsy drug could help prevent the breathing of patients with sleep apnoea from temporarily stopping, according to research. Obstructive sleep apnoea is a common breathing problem that affects about one in 20 people, according to the National Institute for Health and Care Excellence in England. Patients often snore loudly, their breathing starts and stops during the night and they may wake up several times. Not only does this cause tiredness but it can also increase the risk of high blood pressure, stroke, heart disease and type 2 diabetes. An international study has identified that an epilepsy medication is associated with a marked reduction in sleep apnoea symptoms. The findings, presented at the European Respiratory Society Congress in Vienna, Austria, demonstrated there were possible options for those unable to use mechanical breathing aids such as continuous positive airway pressure (Cpap) machines. Prof Jan Hedner, from Sahlgrenska university hospital and the University of Gothenburg in Sweden, said: “The standard treatment for obstructive sleep apnoea is sleeping with a machine that blows air through a face mask to keep the airways open. Unfortunately, many people find these machines hard to use over the long term, so there is a need to find alternative treatments.” The researchers conducted a randomised controlled trial of almost 300 obstructive sleep apnoea patients in Belgium, the Czech Republic, France, Germany and Spain who did not use the Cpap machines. They were divided into four groups and given one of three strengths of sulthiame or a placebo. © 2024 Guardian News & Media Limited

Keyword: Sleep
Link ID: 29474 - Posted: 09.11.2024

By Christina Caron Patients and caregivers have struggled for two years to find stimulant medications like Adderall, Vyvanse and Concerta to treat attention deficit hyperactivity disorder. Some spend hours each month going from pharmacy to pharmacy to find a drug, while others are forced to switch to a different brand or formulation, or go without medication for weeks. This week the Drug Enforcement Administration announced a potential solution: It is raising the amount of lisdexamfetamine (Vyvanse) that can be produced by U.S. manufacturers this year by nearly 24 percent to meet demand in the United States and abroad. Vyvanse is an amphetamine that has been approved for use in children and adults with A.D.H.D. and has become commonly prescribed after the generic version was introduced last year. According to the D.E.A., the latest data shows that demand for the drug has been rising globally. But right now every manufacturer of generic Vyvanse listed on the Food and Drug Administration website is experiencing a shortage. Many health care providers who specialize in treating patients with A.D.H.D. said that the D.E.A.’s decision was a positive development but that it was unclear just how much of an effect it might have on the shortage. “Obviously it’s not going to solve the problem completely,” said Ami Norris-Brilliant, clinical director of the Division of A.D.H.D., Learning Disorders, and Related Disorders at the Icahn School of Medicine at Mount Sinai in New York City. “But I think anything that helps increase drug availability is a good thing.” It is not the first time that the D.E.A. has increased production quotas for A.D.H.D. drugs. Last year it announced a new 2023 limit for methylphenidate, which is used to make drugs like Ritalin and Concerta, raising the allotted amount by 27 percent for 2023. The drug remains in shortage, however, in the extended release formulation. © 2024 The New York Times Company

Keyword: ADHD
Link ID: 29473 - Posted: 09.11.2024

By Olivia Gieger Unlike traditional antidepressants, ketamine acts quickly to relieve depression symptoms, and its effects last long after the drug has cleared the system. Researchers have puzzled over what ketamine is doing in the brain to achieve these results. For one thing, the drug acts on N-methyl-D-aspartate (NMDA) glutamate receptors, which appear on neurons all over the brain. “Then the question is: Does the drug hit on all these brain regions simultaneously?” says Hailan Hu, professor of brain science at Zhejiang University. Or does it affect one region first, which sets off a series of downstream antidepressant effects? The answer is the latter, Hu and her colleagues report in a new study. Ketamine acts first on neurons in the lateral habenula, they found, in mice with depression-like symptoms. The structure—known as the “anti-reward” center—is hyperactive in people with depression and in mice modeling the condition, previous work has shown. That activity makes it highly susceptible to the drug’s effects, Hu and her colleagues discovered. Ketamine binds the NMDA receptors of cells in the lateral habenula and renders them inactive, which in turn interrupts downstream mechanisms of depression. The findings, published in Science in August, help explain how the known targets of ketamine are involved in such a rapid antidepressant response, explains Christophe Proulx, associate professor of psychiatry and neuroscience at Laval University. Proulx was not involved in the work but co-authored a Perspective article on it. Spotlighting the lateral habenula’s role also represents a new way of thinking about ketamine’s effects on depression—involving a shift away from a focus on weakened circuits and impaired plasticity, says Todd Gould, professor of psychiatry and neurobiology at the University of Maryland School of Medicine, who was not affiliated with the study. “[The work provides] additional strong evidence supporting a different view about how ketamine may be working.” Although ketamine inactivated NMDA receptors in the lateral habenula of the depressive-like mice, it had less impact in the CA1 region of the hippocampus, Hu and her colleagues observed using in-vitro slice electrophysiology and electrode recordings in awake animals. © 2024 Simons Foundation

Keyword: Depression
Link ID: 29472 - Posted: 09.11.2024

By Roni Caryn Rabin Move over, body mass index. Make room for roundness — to be precise, the body roundness index. The body mass index, or B.M.I., is a ratio of height to weight that has long been used as a medical screening tool. It is one of the most widely used health metrics but also one of the most reviled, because it is used to label people overweight, obese or extremely obese. The classifications have been questioned by athletes like the American Olympic rugby player Ilona Maher, whose B.M.I. of 30 technically puts her on the cusp of obesity. “But alas,” she said on Instagram, addressing online trolls who tried to shame her about her weight, “I’m going to the Olympics and you’re not.” Advocates for overweight individuals and people of color note that the formula was developed nearly 200 years ago and based exclusively on data from men, most of them white, and that it was never intended for medical screening. Even physicians have weighed in on the shortcomings of B.M.I. The American Medical Association warned last year that B.M.I. is an imperfect metric that doesn’t account for racial, ethnic, age, sex and gender diversity. It can’t differentiate between individuals who carry a lot of muscle and those with fat in all the wrong places. “Based on B.M.I., Arnold Schwarzenegger when he was a bodybuilder would have been categorized as obese and needing to lose weight,” said Dr. Wajahat Mehal, director of the Metabolic Health and Weight Loss Program at Yale University. “But as soon as you measured his waist, you’d see, ‘Oh, it’s 32 inches.’” So welcome a new metric: the body roundness index. B.R.I. is just what it sounds like — a measure of how round or circlelike you are, using a formula that takes into account height and waist, but not weight. © 2024 The New York Times Company

Keyword: Obesity
Link ID: 29471 - Posted: 09.07.2024

By Cassandra Willyard Megan Hodge’s first bout of intense pain arrived when she was in her mid-20s. Hodge and her husband were getting ready to visit family for Thanksgiving. Though Hodge had been dealing with a variety of chronic health issues, her workout had gone well that morning and she finally felt like she was getting a handle on her health. Hodge began packing. As she reached into her closet to grab a sweater, her back gave out. The pain was excruciating, so intense that she felt light-headed and thought she might vomit. As the years passed, Hodge had more frequent and more severe bouts of back pain. Any small movement could be a trigger — grabbing a towel from the linen closet, picking up a toy off the floor, sneezing. In 2021, Hodge experienced a particularly bad flare-up. None of the strategies she had previously used to help her manage seemed to be working. She was afraid to make any movement. She felt hopeless. “I just could not regain footing, metaphorically and physically,” she says. “I truly felt frozen in my chronic pain and chronic health journey.” Hodge is far from alone. In the United States, chronic pain affects tens of millions of people — about 1 in 5 adults and nearly 1 in 3 people ages 65 and older. “The amount of suffering from arthritis and aging that I’ve seen in my pain clinic, it’s overwhelming to me as a pain doctor,” says Antje Barreveld, an anesthesiologist at Mass General Brigham’s Newton-Wellesley Hospital in Massachusetts. What’s more, the mainstay therapy for severe acute and chronic pain — prescription opioids — has helped fuel an epidemic that kills tens of thousands of people each year. “We have to have some better alternatives,” she says. So researchers have doubled down in their quest to find new pain treatments that aren’t as addictive as opioids. “The pain field has really made very rapid and tremendous progress in the last decade,” says D.P. Mohapatra, a former pain scientist who now oversees research at the National Institute of Neurological Disorders and Stroke in Bethesda, Md. © Society for Science & the Public 2000–2024.

Keyword: Pain & Touch; Drug Abuse
Link ID: 29470 - Posted: 09.07.2024